Our research group has recently reported that 47% of ovarian tumors tested by immunohistochemistry (IHC) expressed moderate-to-strong TROP2 expression (i.e., 2+ and 3+) while an additional 40% demonstrated 1+ TROP2 staining (total 1+/2+/3+ TROP2 positivity in ovarian cancer = 87%) [3,4]. Here, TACSTD2 is linked to ovarian carcinoma.